Science

PSOGI Highlights CAIRO-6 Trial Outcomes on HIPEC and Chemotherapy in Colorectal Peritoneal Metastases

istockphoto.com

Jun 2, 2025, 09:07

PSOGI Highlights CAIRO-6 Trial Outcomes on HIPEC and Chemotherapy in Colorectal Peritoneal Metastases

Peritoneal Surface Oncology Group International (PSOGI) shared a post on LinkedIn:

“Congratulations to the investigators of CAIRO-6.

Cytoreductive Surgery CRS+HIPEC in patients with colorectal PERITONEAL metastases vs CRS+HIPEC and peri-operative systemic chemotherapy

5 Median F/U of 41M
Did not meet endpoint for OS
OS of 54M vs 45M (NS)

– mPFS 14 vs 7 mo
– mDFS 12 vs 7 mo
– mOS 44 vs 39 mo
– No OS benefit in IIT, but better OS in synchronous right-sided tumors

Highest reported OS in a RCT- 45-54 months validation/ endorsement of Results.”

hipec

Title: Comparison of Neoadjuvant Systemic Chemotherapy Protocols for the Curative-Intent Management of Peritoneal Metastases from Colorectal Cancer, Regarding Morphological Response, Pathological Response, and Long-Term Outcomes: A Retrospective Study

Authors: Florian Fanget, Amaniel Kefleyesus, Julien Peron, Isabelle Bonnefoy, Laurent Villeneuve, Guillaume Passot, Pascal Rousset, Benoit You, Nazim Benzerdjeb, Olivier Glehen, Vahan Kepenekian

Read Full Article.

HIPEC

Title: Patterns and Timing of Recurrence following CRS and HIPEC in Colorectal Cancer Peritoneal Metastasis

Authors: Sarah Hassan, Lee Malcomson, Yen Jia Soh, Malcom S Wilson, Hamish Clouston, Sarah T O’Dwyer, Rohit Kochhar, Omer Aziz

Read Full Article.

PSOGI Highlights CAIRO-6 Trial Outcomes on HIPEC and Chemotherapy in Colorectal Peritoneal Metastases

Title: Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy and Liver Resection is a Treatment Option for Patients With Peritoneal and Liver Metastases From Colorectal Cancer

Authors: Vegar Johansen Dagenborg, Kristoffer Watten Brudvik, Christin Lund-Andersen, Annette Torgunrud, Marius Lund-Iversen, Kjersti Flatmark, Stein Gunnar Larsen, Sheraz Yaqub

Read Full Article.

PSOGI Highlights CAIRO-6 Trial Outcomes on HIPEC and Chemotherapy in Colorectal Peritoneal Metastases

The CAIRO-6 study, highlighted by PSOGI, compared outcomes of cytoreductive surgery and HIPEC with and without peri-operative systemic chemotherapy in colorectal peritoneal metastases.

While overall survival (OS) endpoints were not met, the trial reported improved median progression-free survival (mPFS) and disease-free survival (mDFS) in the chemotherapy arm.

Endorsements and validations of the findings came from multiple European centers.

More posts featuring Colorectal Cancer on OncoDaily.